Hormonal therapy remains the remedy of very first choice for metastatic individuals with endocrine-responsive breast cancer (LoE 1a A, AGO ++). The sequential use from the offered medicines is determined by the individual pretreatment. Reassessment of ER, PR, and HER2 in tumor tissue at the time of diagnosis of https://wardp642nvc9.wssblogs.com/profile